Mayzent

(Siponimod)

Phase 3Small molecule

Novartis

Mayzent is one of 80 small molecule programs targeting Alzheimer's Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Alzheimer's DiseaseRecruiting

Multiple SclerosisActive, not recruiting

Secondary Progressive Multiple SclerosisActive, not recruiting

Alzheimer's DiseasePhase 2

Recruiting

Multiple SclerosisPhase 3

Active, not recruiting

Secondary Progressive Multiple SclerosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

138 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

Rinvoq

AbbVie

Phase 3

1 2

Cytoxan

BBaxter Healthcare Corporation

Phase 3

9 3

Questran

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

2 4

Versed

CConrado Roberto Hoffmann Filho

Phase 3

2 5

Vumerity

Biogen

Phase 3

5 6

Activated Charcoal

Sanofi

Phase 3

1 7

Antihistamine

Arrowhead Pharmaceuticals

Phase 3

2 8

Mayzent

Novartis

Phase 3

2 9

MRI Contrast-Enhancing Agents

Sanofi

Phase 3

3 10

Frexalimab

Sanofi

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 2Recruiting

Alzheimer's Disease

NCT06639282

Q1 2031

Active, not recruiting

Multiple Sclerosis

NCT05688436

Phase 3Active, not recruiting

Multiple Sclerosis

NCT04926818

Clinical

Trials by Indication[1]

Multiple Sclerosis2 trials

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

Active, not recruiting· Novartis logo

Novartis·Phase 3·NCT04926818·129 enrolled

Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

Active, not recruiting· Biogen logo

Biogen··NCT05688436·1,178 enrolled

Alzheimer's Disease1 trial

Repurposing Siponimod for Alzheimer's Disease

Recruiting·SSt. Joseph's Hospital and Medical Center, Phoenix·Phase 2·NCT06639282·105 enrolled

Infusion1 trial

Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients

Completed· Novartis logo

Novartis·Phase 3·NCT03623243·185 enrolled

Secondary Progressive Multiple Sclerosis1 trial

Managed Access Program (MAP) for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With Active Disease

No longer available· Novartis logo

Novartis··NCT04540861

Regulatory

FDA Approval Timeline[4]

Mar 26, 2019

MAYZENT

NDA NDA209884

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Siponimod. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Siponimod compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Siponimod. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA209884). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Mayzent. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Novartis

Patent Landscape[5]

Patent Cliff

Aug 27, 2028

Earliest patent expiration — generic entry possible after this date

Patent #Expires

7939519Aug 27, 2028

8492441Nov 30, 2030

12071402Jan 5, 2032

12533340Apr 23, 2036

11944602Apr 23, 2036

Mayzent

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Q1 2031

Trials by Indication[1]

Multiple Sclerosis2 trials

Alzheimer's Disease1 trial

Infusion1 trial

Secondary Progressive Multiple Sclerosis1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News